We are recruiting participants with Crohn’s disease for a clinical trial to test a potential new treatment.

A new clinical trial for ulcerative colitis accepting participants to study QBECO SSI treatment.

A total of 122 patients have received QBECO SSI treatment. Learn more about the safety and effectiveness to date.

  • Very good safety profile to date
  • 10 people with Crohn's disease were treated through a compassionate use program
  • 7 of the 10 had clinical remission
  • 4 have had sustained clinical remission after discontinuing all treatments
  • The longest case of remission is ongoing after nearly 3 years

Investigational treatment for Crohn’s Disease and Ulcerative Colitis

Our clinical trial involves Site Specific Immunomodulators (SSIs), a novel class of immunotherapy treatment. SSIs are being developed to stimulate the immune system in a targeted manner to reverse the chronic inflammation underlying many conditions, such as Crohn’s disease.

Sixty participants are being recruited into a Phase 1/2 clinical trial for the treatment of Crohn's disease. The trial is open to Canadian and U.S. residents living with Crohn's disease. Learn more about who can participate in this clinical trial.

A Phase 2a open label clinical trial for ulcerative colitis to study QBECO SSI treatment is now accepting participants. This study is open to Canadian residents.

Listen to an interview with Dr. Hal Gunn